We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-1.19%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.78B
AUM Growth
-$1.32B
Cap. Flow
-$329M
Cap. Flow %
-4.22%
Top 10 Hldgs %
29.03%
Holding
186
New
13
Increased
33
Reduced
45
Closed
29

Top Buys

Rank Stock Value
1
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$254M
2
PFE icon
Pfizer
PFE
+$130M
3
CMPX icon
Compass Therapeutics
CMPX
+$71.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$64.9M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$61.9M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$156M
2
ELV icon
Elevance Health
ELV
+$77.2M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$74.2M
4
PGNY icon
Progyny
PGNY
+$71.1M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$68.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.32%
2 Industrials 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
26
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$100M 1.29%
2,106,450
-254,877
-11% -$11.4M
HCA icon
27
HCA Healthcare
HCA
$91.8B
$100M 1.29%
389,500
+195,700
+101% +$47.9M
TCDA
28
DELISTED
Tricida, Inc. Common Stock
TCDA
$98.3M 1.26%
10,280,947
+666,667
+7% +$4.3M
KROS icon
29
Keros Therapeutics
KROS
$196M
$98.3M 1.26%
1,679,417
– –
CRNX icon
30
Crinetics Pharmaceuticals
CRNX
$8.88B
$90.8M 1.17%
3,196,876
+200,000
+7% +$4.93M
MGTX icon
31
MeiraGTx Holdings
MGTX
$1.07B
$88.5M 1.14%
3,727,466
-375,459
-9% -$7.19M
DXCM icon
32
DexCom
DXCM
$29.3B
$82.1M 1.06%
611,600
-300,400
-33% -$43.2M
NBIX icon
33
Neurocrine Biosciences
NBIX
$18.2B
$79.4M 1.02%
931,915
-260,100
-22% -$23.9M
BMRN icon
34
BioMarin Pharmaceuticals
BMRN
$12B
$76.1M 0.98%
860,880
+749,980
+676% +$61.9M
SVA
35
DELISTED
Sinovac Biotech, Ltd
SVA
$72.7M 0.93%
2,839,500
– –
ZBH icon
36
Zimmer Biomet
ZBH
$18.7B
$71.7M 0.92%
581,229
-99,395
-15% -$13M
RPTX
37
DELISTED
Repare Therapeutics
RPTX
$70.1M 0.9%
3,322,488
– –
CMPX icon
38
Compass Therapeutics
CMPX
$355M
$68.6M 0.88%
+21,642,975
New +$71.8M
KNTE
39
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$68.2M 0.88%
3,847,929
– –
TBPH icon
40
Theravance Biopharma
TBPH
$875M
$66M 0.85%
5,974,535
+79,376
+1% +$692K
TMO icon
41
Thermo Fisher Scientific
TMO
$215B
$63.2M 0.81%
94,700
-15,600
-14% -$9.74M
ABCL icon
42
AbCellera Biologics
ABCL
$1.62B
$59.8M 0.77%
4,180,768
– –
SPRY icon
43
ARS Pharmaceuticals
SPRY
$552M
$58.2M 0.75%
8,740,887
– –
ALPN
44
DELISTED
Alpine Immune Sciences Inc
ALPN
$56.5M 0.73%
4,081,592
– –
JANX icon
45
Janux Therapeutics
JANX
$900M
$56M 0.72%
2,836,386
-630,000
-18% -$13.2M
BIIB icon
46
Biogen
BIIB
$31.4B
$55.2M 0.71%
230,200
-4,000
-2% -$1.03M
SIBN icon
47
SI-BONE Inc
SIBN
$809M
$51.2M 0.66%
2,305,300
+57,300
+3% +$1.23M
ETNB
48
DELISTED
89bio
ETNB
$48.7M 0.63%
3,729,442
– –
GRCL
49
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$47.6M 0.61%
7,884,870
– –
PASG icon
50
Passage Bio
PASG
$14.2M
$44.2M 0.57%
348,145
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2021 Portfolio in Review

As of Q4 2021, OrbiMed held 186 positions worth $7.78B, down 15% from $9.1B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

OrbiMed withdrew a net $329M in Q4 2021, closing 29 positions and reducing 45 holdings. Its most notable exit was Elevance Health, an estimated $77.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials and Technology.

Against the trend, OrbiMed opened a new position in Theseus Pharmaceuticals, Inc. Common Stock worth $214M.

  • OrbiMed's largest Q4 2021 buy was Theseus Pharmaceuticals, Inc. Common Stock: 16,838,668 shares worth $214M.
  • OrbiMed added most to Seagen Inc. Common Stock in Q4 2021, an estimated $64.9M increase.
  • OrbiMed's biggest Q4 2021 reduction was Merck, cutting an estimated $156M.
  • OrbiMed fully exited Elevance Health in Q4 2021, selling an estimated $77.2M.
  • OrbiMed's ten largest holdings make up 29% of its $7.78B portfolio in Q4 2021.
  • OrbiMed opened 13 new positions and closed 29 in Q4 2021.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $7.78B.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.